Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Sumatriptan succinate
Drug ID BADD_D02099
Description Sumatriptan is a serotonin receptor agonist commonly used to treat migraines and sometimes cluster headaches.[L6793,L6796,L6799,L6805,L6808,L6811] Sumatriptan is the first of the triptans and was made available in Europe in 1991 to treat migraines.[A179761] Sumatriptan was granted FDA approval on 28 December 1992.[L6805]
Indications and Usage A combination sumatriptan and [naproxen] tablet is indicated for the treatment of migraines with or without auras in patients 12 years of age and older.[L6793] Sumatriptan nasal powder, nasal spray, subcutaneous injection, and tablets are indicated to treat migraines with or without auras in adults.[L6796,L6799,L6805,L6808,L6811] One of the subcutaneous formulations of sumatriptan is also indicated to treat cluster headaches in adults[L6805], while the other subcutaneous formulation is not.[L6808]
Marketing Status approved; investigational
ATC Code N02CC01
DrugBank ID DB00669
KEGG ID D00676
MeSH ID D018170
PubChem ID 59772
TTD Drug ID D0Z6UC
NDC Product Code 52932-0727; 62331-049; 65862-146; 65862-148; 50090-1130; 53002-1592; 55111-693; 0378-5631; 72189-432; 0093-2014; 49574-517; 53104-7581; 53002-2592; 62756-522; 50370-0014; 51552-1376; 55111-060; 65015-860; 65015-864; 16714-796; 43598-768; 51407-011; 51407-013; 62756-520; 63187-931; 68071-2283; 60429-994; 62756-521; 63187-607; 71205-111; 49452-7585; 65862-147; 51407-012; 53002-1562; 53002-2593; 55700-759; 55700-899; 63187-049; 63187-617; 0378-5630; 76420-499; 35356-439; 42847-311; 55111-293; 63187-797; 68788-6778; 70518-1184; 0378-5632; 62756-730; 16714-797; 47335-276; 0245-0809; 55111-291; 55111-292; 63187-969; 68788-9547; 70594-068; 76420-093; 53069-0560; 57315-216; 67835-5010; 16714-798; 50090-2144; 70518-1183; 71205-251; 71205-725; 76420-498; 76420-500; 59651-151; 71205-274; 72189-433; 72603-141; 0093-2013; 65862-371; 50090-1129; 50090-5939; 53002-1593; 53002-2562; 63323-273; 68788-6769; 68788-8205; 70518-2859; 48087-0075; 57315-214; 57315-215; 16714-040; 45865-570; 55700-936
UNII J8BDZ68989
Synonyms Sumatriptan | 3-(2-(Dimethylamino)ethyl)-N-methyl-1H-indole-5-methanesulfonamide | Sumatriptan Succinate | Succinate, Sumatriptan | GR-43175 | GR 43175 | GR43175 | Imigran
Chemical Information
Molecular Formula C18H27N3O6S
CAS Registry Number 103628-48-4
SMILES CNS(=O)(=O)CC1=CC2=C(C=C1)NC=C2CCN(C)C.C(CC(=O)O)C(=O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Neck pain15.03.04.009--
Nephrolithiasis20.04.01.002--
Neuralgia17.02.07.005--
Neurosis19.06.01.001---
Oedema08.01.07.006; 14.05.06.010---
Oedema peripheral02.05.04.007; 08.01.07.007; 14.05.06.011--
Optic ischaemic neuropathy06.07.03.001; 17.04.05.006; 24.04.10.001---
Oral pain07.05.05.034--
Otitis externa04.01.02.001; 11.01.05.003--
Overdose12.11.01.002---
Pain08.01.08.004--
Pain in jaw15.02.01.003---
Pain of skin23.03.03.003--
Pallor08.01.03.032; 23.03.03.031; 24.03.04.001---
Palpitations02.11.04.012--
Pancreatitis07.18.01.001--
Pancytopenia01.03.03.003---
Panic disorder19.06.04.002---
Paraesthesia17.02.06.005; 23.03.03.094--
Paralysis17.01.04.004---
Parosmia17.04.04.002; 22.04.03.007---
Pelvic inflammatory disease11.01.10.006; 21.14.04.001---
Peptic ulcer07.04.07.001---
Personality change17.02.05.019; 19.05.01.006--
Phlebitis12.02.01.002; 24.12.03.004--
Photophobia06.01.01.004; 17.17.02.006--
Photosensitivity reaction23.03.09.003--
Pituitary tumour05.03.05.002; 16.24.01.003---
Pollakiuria20.02.02.007--
Polydipsia05.03.03.002; 14.05.02.001---
The 6th Page    First    Pre   6 7 8 9 10    Next   Last    Total 10 Pages